PMID

Data

Article Title

Organization

Great Therapeutic Potential of Peptidylarginine Deiminase 4 (PAD4) Inhibitors: Treatment of Rheumatoid Arthritis, Epigenetic Tools, Regulation of Pluripotency in Stem Cells, and More.

Therachem Research Medilab (India)

Insights into the mechanism of streptonigrin-induced protein arginine deiminase inactivation.

The Scripps Research Institute-Florida

The development of N-a-(2-carboxyl)benzoyl-N(5)-(2-fluoro-1-iminoethyl)-l-ornithine amide (o-F-amidine) and N-a-(2-carboxyl)benzoyl-N(5)-(2-chloro-1-iminoethyl)-l-ornithine amide (o-Cl-amidine) as second generation protein arginine deiminase (PAD) inhibitors.

The Scripps Research Institute

Peptidylarginine deiminases 4 as a promising target in drug discovery.

Zhejiang Ocean University

Cellular Activity of New Small Molecule Protein Arginine Deiminase 3 (PAD3) Inhibitors.

Yale University

Development of a Selective Inhibitor of Protein Arginine Deiminase 2.

University of Massachusetts Medical School

Inhibitors of protein arginine deiminases and their efficacy in animal models of multiple sclerosis.

University Health Network

Noncovalent Protein Arginine Deiminase (PAD) Inhibitors Are Efficacious in Animal Models of Multiple Sclerosis.

University of Toronto